These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 38640197)
1. The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD. DeFilipp Z; Kim HT; Spyrou N; Katsivelos N; Kowalyk S; Eng G; Kasikis S; Beheshti R; Baez J; Akahoshi Y; Ayuk F; Choe H; Etra A; Grupp SA; Hexner EO; Hogan WJ; Kitko CL; Qayed M; Reshef R; Vasova I; Zeiser R; Young R; Holler E; Ferrara JLM; Nakamura R; Levine JE; Chen YB Blood Adv; 2024 Jul; 8(13):3488-3496. PubMed ID: 38640197 [TBL] [Abstract][Full Text] [Related]
2. A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD. Qayed M; Kapoor U; Gillespie S; Westbrook A; Aguayo-Hiraldo P; Ayuk FA; Aziz M; Baez J; Choe H; DeFilipp Z; Etra A; Grupp SA; Hexner E; Holler E; Hogan WJ; Kowalyk S; Merli P; Morales G; Nakamura R; Pulsipher MA; Schechter T; Shah J; Spyrou N; Srinagesh HK; Wölfl M; Yanik G; Young R; Kitko CL; Ferrara JLM; Levine JE Transplant Cell Ther; 2024 Jun; 30(6):603.e1-603.e11. PubMed ID: 38548227 [TBL] [Abstract][Full Text] [Related]
3. Ruxolitinib for the treatment of acute graft-versus-host disease: a retrospective analysis. Denk A; Edinger M; Weber D; Holler E; Fante M; Meedt E; Gunes S; Poeck H; Mittermaier C; Herr W; Wolff D Ann Hematol; 2024 Aug; 103(8):3071-3081. PubMed ID: 38916740 [TBL] [Abstract][Full Text] [Related]
4. The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease. Srinagesh HK; Özbek U; Kapoor U; Ayuk F; Aziz M; Ben-David K; Choe HK; DeFilipp Z; Etra A; Grupp SA; Hartwell MJ; Hexner EO; Hogan WJ; Karol AB; Kasikis S; Kitko CL; Kowalyk S; Lin JY; Major-Monfried H; Mielke S; Merli P; Morales G; Ordemann R; Pulsipher MA; Qayed M; Reddy P; Reshef R; Rösler W; Sandhu KS; Schechter T; Shah J; Sigel K; Weber D; Wölfl M; Wudhikarn K; Young R; Levine JE; Ferrara JLM Blood Adv; 2019 Dec; 3(23):4034-4042. PubMed ID: 31816061 [TBL] [Abstract][Full Text] [Related]
5. A Day 14 Endpoint for Acute GVHD Clinical Trials. Spyrou N; Akahoshi Y; Kowalyk S; Morales G; Beheshti R; Aguayo-Hiraldo P; Al Malki MM; Ayuk F; Bader P; Baez J; Capellini A; Choe H; DeFilipp Z; Eder M; Eng G; Etra A; Gleich S; Grupp SA; Hexner E; Hoepting M; Hogan WJ; Kasikis S; Katsivelos N; Khan A; Kitko CL; Kraus S; Kwon D; Merli P; Portelli J; Qayed M; Reshef R; Schechter T; Vasova I; Wölfl M; Wudhikarn K; Young R; Holler E; Chen YB; Nakamura R; Levine JE; Ferrara JLM Transplant Cell Ther; 2024 Apr; 30(4):421-432. PubMed ID: 38320730 [TBL] [Abstract][Full Text] [Related]
6. Ruxolitinib for chronic steroid-refractory graft versus host disease: a single center experience. Xue E; Lorentino F; Pavesi F; Assanelli A; Peccatori J; Bernardi M; Corti C; Ciceri F; Lupo Stanghellini MT Leuk Res; 2021 Oct; 109():106642. PubMed ID: 34157510 [TBL] [Abstract][Full Text] [Related]
7. Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD. Akahoshi Y; Spyrou N; Weber D; Aguayo-Hiraldo P; Ayuk F; Chanswangphuwana C; Choe HK; Eder M; Etra AM; Grupp SA; Hexner EO; Hogan WJ; Kitko CL; Kraus S; Al Malki MM; Merli P; Qayed M; Reshef R; Schechter T; Ullrich E; Vasova I; Wölfl M; Zeiser R; Baez J; Beheshti R; Eng G; Gleich S; Katsivelos N; Kowalyk S; Morales G; Young R; Chen YB; Nakamura R; Levine JE; Ferrara JLM Blood; 2024 Aug; 144(9):1010-1021. PubMed ID: 38968143 [TBL] [Abstract][Full Text] [Related]
8. MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. Major-Monfried H; Renteria AS; Pawarode A; Reddy P; Ayuk F; Holler E; Efebera YA; Hogan WJ; Wölfl M; Qayed M; Hexner EO; Wudhikarn K; Ordemann R; Young R; Shah J; Hartwell MJ; Chaudhry MS; Aziz M; Etra A; Yanik GA; Kröger N; Weber D; Chen YB; Nakamura R; Rösler W; Kitko CL; Harris AC; Pulsipher M; Reshef R; Kowalyk S; Morales G; Torres I; Özbek U; Ferrara JLM; Levine JE Blood; 2018 Jun; 131(25):2846-2855. PubMed ID: 29545329 [TBL] [Abstract][Full Text] [Related]
9. Differences in Acute Graft-Versus-Host Disease (GVHD) Severity and Its Outcomes Between Black and White Patients. Rios CAO; Qayed M; Etra AM; Reshef R; Newcomb R; Yuhasz N; Hexner EO; Aguayo-Hiraldo P; Merli P; Hogan WJ; Weber D; Kitko CL; Ayuk F; Eder M; Grupp SA; Kraus S; Sandhu K; Ullrich E; Vasova I; Wölfl M; Baez J; Beheshti R; Eng G; Gleich S; Katsivelos N; Kowalyk S; Louloudis IE; Morales G; Spyrou N; Young R; Nakamura R; Levine JE; Ferrara JLM; Akahoshi Y Transplant Cell Ther; 2024 Nov; 30(11):1061.e1-1061.e10. PubMed ID: 39222793 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host Disease. Zewde MG; Morales G; Gandhi I; Özbek U; Aguayo-Hiraldo P; Ayuk F; Baez J; Chanswangphuwana C; Choe H; DeFilipp Z; Etra A; Grupp S; Hexner EO; Hogan W; Javorniczky NR; Kasikis S; Kitko CL; Kowalyk S; Meedt E; Merli P; Nakamura R; Qayed M; Reshef R; Rösler W; Schechter T; Weber D; Wölfl M; Yanik G; Young R; Levine JE; Ferrara JLM; Chen YB Transplant Cell Ther; 2021 Dec; 27(12):988.e1-988.e7. PubMed ID: 34474163 [TBL] [Abstract][Full Text] [Related]
11. Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 study. Locatelli F; Antmen B; Kang HJ; Koh K; Takahashi Y; Kupesiz A; Dias Matos MGA; Chopra Y; Bhat S; Im HJ; Güngör T; Lu MY; Stefanelli T; Rosko C; St Pierre A; Burock K; Smith Y; Sinclair K; Diaz-de-Heredia C Lancet Haematol; 2024 Aug; 11(8):e580-e592. PubMed ID: 39002551 [TBL] [Abstract][Full Text] [Related]
12. Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients. Wei C; Zhang X; Liang D; Yang J; Du J; Yue C; Deng L Drug Des Devel Ther; 2021; 15():4875-4883. PubMed ID: 34880598 [TBL] [Abstract][Full Text] [Related]
13. Ruxolitinib-corticosteroid as first-line therapy for newly diagnosed high-risk acute graft versus host disease: study protocol for a multicenter, randomized, phase II controlled trial. Dou L; Peng B; Li X; Wang L; Jia M; Xu L; Li F; Liu D Trials; 2022 Jun; 23(1):470. PubMed ID: 35668528 [TBL] [Abstract][Full Text] [Related]
14. Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia. Zhang B; Chen L; Zhou J; Zu Y; Gui R; Li Z; Wang J; Yu F; Zhang Y; Zhao H; Ji Z; Song Y Sci Rep; 2021 Apr; 11(1):8501. PubMed ID: 33875780 [TBL] [Abstract][Full Text] [Related]
15. Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness. Mohty M; Holler E; Jagasia M; Jenq R; Malard F; Martin P; Socié G; Zeiser R Blood; 2020 Oct; 136(17):1903-1906. PubMed ID: 32756949 [TBL] [Abstract][Full Text] [Related]
16. Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial. Teshima T; Onishi Y; Kato K; Taniguchi S; Miyamura K; Fukushima K; Kato J; Ishikawa T; Doki N; Nakamae H; Maeda Y; Inamoto Y; Okada M; Maki A; Shimada F; Tajima T; Wroclawska M; Zeiser R; Onizuka M Int J Hematol; 2024 Jul; 120(1):106-116. PubMed ID: 38796666 [TBL] [Abstract][Full Text] [Related]
17. Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628). von Bubnoff N; Ihorst G; Grishina O; Röthling N; Bertz H; Duyster J; Finke J; Zeiser R BMC Cancer; 2018 Nov; 18(1):1132. PubMed ID: 30453910 [TBL] [Abstract][Full Text] [Related]
18. Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis. Akahoshi Y; Spyrou N; Hoepting M; Aguayo-Hiraldo P; Ayuk F; Chanswangphuwana C; Choe HK; Eder M; Etra AM; Grupp SA; Hexner EO; Hogan WJ; Kitko CL; Kraus S; Al Malki MM; Merli P; Qayed M; Reshef R; Schechter T; Ullrich E; Vasova I; Wölfl M; Zeiser R; Baez J; Beheshti R; Eng G; Gleich S; Kasikis S; Katsivelos N; Kowalyk S; Morales G; Young R; DeFilipp Z; Ferrara JLM; Levine JE; Nakamura R Blood Adv; 2024 Apr; 8(8):2047-2057. PubMed ID: 38324721 [TBL] [Abstract][Full Text] [Related]
19. Ruxolitinib in the management of steroid-resistant/-dependent acute and chronic graft-versus-host disease: results of routine practice in an academic centre. Leung GMK; Sim JPY; Hwang YY; Chan TSY; Lie AKW; Tse E; Kwong YL Ann Hematol; 2022 Jan; 101(1):155-163. PubMed ID: 34767056 [TBL] [Abstract][Full Text] [Related]
20. Ruxolitinib in patients with graft versus host disease (GvHD): findings from a compassionate use program. Pattipaka T; Sarp S; Nakhaei P; Güneş S Bone Marrow Transplant; 2024 May; 59(5):637-646. PubMed ID: 38361117 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]